Company Lowers 2026 EPS Guidance by Approximately $9.50
Previous guidance was $8.45-$8.85. "As compared to our February guidance, our updated full year 2026 GAAP and non-GAAP diluted earnings per share guidance was reduced by approximately $9.50 due to the anticipated acquired IPR&D charges of $11.5 billion as well as financing costs related to the Arcellx, Inc, Ouro Medicines, LLC, and Tubulis GmbH transactions."